SHR1701
SHR1701 is a pharmaceutical drug with 27 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
9
Early Stage
17
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
2 of 3 finished
33.3%
1 ended early
3
trials recruiting
27
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
Clinical Trials (27)
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer
Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
SHR-1701 Combined with SHR2554 and BP102 for MCRC
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 27